Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
12 December 2024 | Story André Damons | Photo André Damons
Dr Innocensia Mangoato
Dr Innocensia Mangoato graduated on Tuesday (10 December 2024) with degree Doctor of Philosophy with specialisation in pharmacology at the Faculty of Health Sciences’ December graduation ceremony. Here she is with her supervisor and mentor Prof Motlalepula Matsabisa, Director of the University of the Free State (UFS) Department of Pharmacology.

A lecturer and researcher from the University of the Free State (UFS) Department of Pharmacology hopes her research into the use of cannabis in reversing anticancer drug resistance is a step forward into treating various cancers especially in Southern Africa.

Dr Innocensia Mangoato graduated on Tuesday (10 December 2024) with the degree Doctor of Philosophy with specialisation in pharmacology at the Faculty of Health Sciences’ December graduation ceremony. She started her career as a research scientist in the area of African traditional medicines in 2018 and her research received both national and international recognition.

“It’s an amazing (feeling to graduate today). My PhD journey was smooth and beautiful and with mentorship of Prof (Motlalepula) Matsabisa, who groomed me well, I did not shed a tear,” said Dr Mangoato. Dr Gudrun S Ulrich-Merzenich from the University of Bonn in Germany, was her co-supervisor with Prof Matsabisa.

According to the graduation programme, Dr Mangoato, Lecturer and Researcher in the UFS Department of Pharmacology, with her thesis titled Investigating the anticancer and possible resistant reversal effects of cannabis sativa l. extracts in cervical cancer cell lines and modulation of ABC transporters comprehensively explored the therapeutic potential of Cannabis sativa L. in overcoming drug resistance in cervical cancer using in vitro and network pharmacology approaches.

A step forward for treating various cancers

The research looked at the chemical fingerprints and pharmacological targets of C. sativa L. extracts, highlighting its antiproliferative properties against normal non-cancerous cells, cervical cancer cells and the cisplatin-resistant cervical cancer cells. Through PCR analysis, distinct gene expression profiles were identified, revealing the potential effects of combination treatments to counteract cisplatin resistance by downregulating genes associated with drug transporters and crucial signalling pathways. This work provides valuable insights into innovative therapeutic strategies for improving cervical cancer treatment, highlighting new avenues for overcoming resistance and enhancing treatment efficacy though the possible use of plant extracts.

“I hope my research takes a step forward in treating various cancers – especially gynaecology cancers in the Southern Hemisphere in Africa. Hopefully the research can later transcend into clinical trials and hopefully influence more policymakers. We also hope to further develop cannabis to be used as an adjuvant therapy for those drugs that are failing to treat cancer,” says Dr Mangoato, who was the recipient of the Women in Science Master’s Student in 2018.

Her graduation was also a proud moment for Prof Matsabisa, an expert in traditional African medicine, who was like a father to her during her studies. “Prof identified me from my honours degree and walked this journey with me. He has been a great mentor, a father and an amazing supervisor.”

Dr Mangoato says she will for now focus on research only and helping and monitoring upcoming researchers, especially female researchers as there is a scarcity of them her field. 

News Archive

UFS presents unique rally
2006-05-11

On Friday 9 June 2006 the University of the Free State (UFS) will present the second Amazing Race Rally in Bloemfontein. 

The rally is presented in aid of children and babies with serious diseases in the Department of Pediatrics and Child Health in the UFS Faculty of Health Sciences.  These children are in need of intensive care, and suffer from cancer, heart disease, neurological diseases and conditions, endocrinological diseases or gastro-enterological conditions.

By raising the necessary funds, equipment can be acquired to meet the unique healthcare needs of these children and babies and it will also enable the UFS to maintain the high standards of education, training and research in this field.

Last year about 12 corporate teams from among others Vodacom, Medi-Clinic, Eskom, Mimosa Mall and Nedbank and four teams from the UFS competed in the rally.  The Medi-Clinic team was the winner.

This year the teams will again follow a specific route with various check points by car.  Here they will have to complete activities or solve clues before receiving their clue to the next checkpoint.  The teams will be travelling with cars branded with the logo of the company they represent.

Companies and institutions in Bloemfontein can enter in the rally by means of sponsoring a check point, entering a team of two persons or sponsoring some aspects of the day. 

The rally will give participants an opportunity to test their knowledge of the city, as well as their time management skills, communication skills, team work and even their relationships! 

The programme will start at 12:00 on the UFS Main Campus and the first team to complete this task is the winner of Bloemfontein’s second Amazing Rainbow Rally.

Extensive publicity of the event on OFM in the weeks running up to the day will ensure that participants are easily recognised and will create a measure of excitement.

Enquiries about the rally can be directed to Ms Adéle van Aswegen at (051) 401-3535 or Ms Ilse Olivier at (051) 401-2415.

Media release
Issued by: Lacea Loader
Media Representative
Tel:  (051) 401-2584
Cell:  083 645 2454
E-mail:  loaderl.stg@mail.uovs.ac.za
11 May 2006

 

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept